Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

References

• Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol Ther 2014; 142:258 - 69; http://dx.doi.org/10.1016/j.pharmthera.2013.12.010; PMID: 24362082
   PubMed Web of Science ®Google Scholar
• Petronczki M, Lénárt P, Peters JM. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell 2008; 14:646 - 59; http://dx.doi.org/10.1016/j.devcel.2008.04.014; PMID: 18477449
   PubMed Web of Science ®Google Scholar
• Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and Aurora kinases in cancer. Nat Rev Cancer 2010; 10:825 - 41; http://dx.doi.org/10.1038/nrc2964; PMID: 21102634
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24:267 - 76; http://dx.doi.org/10.1038/sj.onc.1208273; PMID: 15640842
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003; 4:842 - 54; http://dx.doi.org/10.1038/nrm1245; PMID: 14625535
   PubMed Web of Science ®Google Scholar
• Tatsuka M, Sato S, Kitajima S, Suto S, Kawai H, Miyauchi M, Ogawa I, Maeda M, Ota T, Takata T. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005; 24:1122 - 7; http://dx.doi.org/10.1038/sj.onc.1208293; PMID: 15592510
   PubMed Web of Science ®Google Scholar
• Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14:1639 - 48; http://dx.doi.org/10.1158/1078-0432.CCR-07-2179; PMID: 18347165
   PubMed Web of Science ®Google Scholar
• Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS. Targeting Aurora kinases in cancer treatment. Curr Drug Targets 2011; 12:2067 - 78; http://dx.doi.org/10.2174/138945011798829410; PMID: 21777198
   PubMed Web of Science ®Google Scholar
• Tang CJ, Lin CY, Tang TK. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006; 290:398 - 410; http://dx.doi.org/10.1016/j.ydbio.2005.11.036; PMID: 16386730
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010; 70:1513 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-09-2181; PMID: 20145140
   PubMed Web of Science ®Google Scholar
• Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, et al. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol 2013; 163:214 - 22; PMID: 24033250
   PubMed Web of Science ®Google Scholar
• Hartsink-Segers SA, Exalto C, Allen M, Williamson D, Clifford SC, Horstmann M, Caron HN, Pieters R, Den Boer ML. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica 2013; 98:1539 - 46; http://dx.doi.org/10.3324/haematol.2013.084434; PMID: 23753023
   PubMed Web of Science ®Google Scholar
• Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011; 155:561 - 79; http://dx.doi.org/10.1111/j.1365-2141.2011.08898.x; PMID: 21980926
   PubMed Web of Science ®Google Scholar
• Marzo I, Naval J. Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Biochem Pharmacol 2013; 86:703 - 10; http://dx.doi.org/10.1016/j.bcp.2013.07.010; PMID: 23886991
   PubMed Web of Science ®Google Scholar
• Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, et al. A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis. Clin Lymphoma Myeloma Leuk 2013. doi: http://dx.doi.org/10.1016/j.clml.2013.11.001.
   Google Scholar
• Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, et al, SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 2013; 119:2611 - 9; http://dx.doi.org/10.1002/cncr.28113; PMID: 23605952
   PubMed Web of Science ®Google Scholar
• Chen YP, Lin HJ, Chen JS, Tsai MY, Hsieh HP, Chang JY, Chen NF, Chang KC, Huang WT, Su WC, et al. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. Int J Cancer 2013; PMID: 24382688
   PubMed Web of Science ®Google Scholar
• Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer 2012; 11:42; http://dx.doi.org/10.1186/1476-4598-11-42; PMID: 22721004
   PubMed Web of Science ®Google Scholar
• Uckun FM, Ozer Z, Qazi S, Tuel-Ahlgren L, Mao C. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress. Br J Haematol 2010; 148:714 - 25; http://dx.doi.org/10.1111/j.1365-2141.2009.07983.x; PMID: 19912216
   PubMed Web of Science ®Google Scholar
• Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood 2012; 120:1165 - 74; http://dx.doi.org/10.1182/blood-2012-05-378943; PMID: 22730540
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013; 14:e205 - 17; http://dx.doi.org/10.1016/S1470-2045(12)70580-6; PMID: 23639321
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012; 122:3398 - 406; http://dx.doi.org/10.1172/JCI61269; PMID: 23023710
   PubMed Web of Science ®Google Scholar
• Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3:371 - 94; PMID: 22564882
   PubMed Web of Science ®Google Scholar
• Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011; 71:1385 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-10-2484; PMID: 21303981
   PubMed Web of Science ®Google Scholar
• Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC, Anderson ML. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 2012; 18:3352 - 65; http://dx.doi.org/10.1158/1078-0432.CCR-11-3058; PMID: 22535157
   PubMed Web of Science ®Google Scholar
• Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 2010; 53:3973 - 4001; http://dx.doi.org/10.1021/jm901870q; PMID: 20420387
   PubMed Web of Science ®Google Scholar
• Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26:2336 - 42; http://dx.doi.org/10.1038/leu.2012.136; PMID: 22614243
   PubMed Web of Science ®Google Scholar
• Malaguti P, Vari S, Cognetti F, Fabi A. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res 2013; 33:21 - 8; PMID: 23267124
   PubMed Web of Science ®Google Scholar
• Macůrek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH. Polo-like kinase-1 is activated by Aurora A to promote checkpoint recovery. Nature 2008; 455:119 - 23; http://dx.doi.org/10.1038/nature07185; PMID: 18615013
   PubMed Web of Science ®Google Scholar
• Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 2012; 11:700 - 9; http://dx.doi.org/10.1158/1535-7163.MCT-11-0762; PMID: 22188812
   PubMed Web of Science ®Google Scholar
• Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, et al. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Mol Cancer Ther 2013; 12:460 - 70; http://dx.doi.org/10.1158/1535-7163.MCT-12-0657; PMID: 23358665
   PubMed Web of Science ®Google Scholar
• Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud Ø. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?. Expert Opin Investig Drugs 2012; 21:587 - 603; http://dx.doi.org/10.1517/13543784.2012.668525; PMID: 22424119
   PubMed Web of Science ®Google Scholar
• Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009; 12:103 - 13; http://dx.doi.org/10.1016/j.drup.2009.06.001; PMID: 19632887
   PubMed Web of Science ®Google Scholar
• Suzuki J, Fujita J, Taniguchi S, Sugimoto K, Mori KJ. Characterization of murine hemopoietic-supportive (MS-1 and MS-5) and non-supportive (MS-K) cell lines. Leukemia 1992; 6:452 - 8; PMID: 1375698
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol 2014; 164:767 - 78; http://dx.doi.org/10.1111/bjh.12725; PMID: 24405087
   PubMed Web of Science ®Google Scholar
• Leonard MK, Hill NT, Bubulya PA, Kadakia MP. The PTEN-Akt pathway impacts the integrity and composition of mitotic centrosomes. Cell Cycle 2013; 12:1406 - 15; http://dx.doi.org/10.4161/cc.24516; PMID: 23574721
   PubMed Web of Science ®Google Scholar
• Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V, Gschaider M, Stingl G, Ramaswamy S, Wagner SN. Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol 2011; 131:1886 - 95; http://dx.doi.org/10.1038/jid.2011.136; PMID: 21654832
   PubMed Web of Science ®Google Scholar
• Zeng Z, Sarbassov D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109:3509 - 12; http://dx.doi.org/10.1182/blood-2006-06-030833; PMID: 17179228
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310 - 22; http://dx.doi.org/10.1016/j.molcel.2010.09.026; PMID: 20965424
   PubMed Web of Science ®Google Scholar
• Kang NJ, Lee KW, Rogozin EA, Cho YY, Heo YS, Bode AM, Lee HJ, Dong Z. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 2007; 282:32856 - 66; http://dx.doi.org/10.1074/jbc.M701459200; PMID: 17724030
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3:1068 - 111; PMID: 23085539
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012; 3:954 - 87; PMID: 23006971
   PubMed Web of Science ®Google Scholar
• Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Damanhouri GA, Abuzenadah AM, Chaudhary AG, Sheikh IA. New anticancer agents: recent developments in tumor therapy. Anticancer Res 2012; 32:2999 - 3005; PMID: 22753764
   PubMed Web of Science ®Google Scholar
• Rao CV, Kurkjian CD, Yamada HY. Mitosis-targeting natural products for cancer prevention and therapy. Curr Drug Targets 2012; 13:1820 - 30; http://dx.doi.org/10.2174/138945012804545533; PMID: 23140292
   PubMed Web of Science ®Google Scholar
• Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr 2013; 32:888 - 93; http://dx.doi.org/10.1016/j.clnu.2013.04.007; PMID: 23647723
   PubMed Web of Science ®Google Scholar
• Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010; 16:384 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-1380; PMID: 20068088
   PubMed Web of Science ®Google Scholar
• Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 2013; 4:830 - 43; PMID: 23919981
   PubMed Web of Science ®Google Scholar
• Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, McCubrey JA, Manzoli FA. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Adv Biol Regul 2012; 52:214 - 27; http://dx.doi.org/10.1016/j.advenzreg.2011.09.019; PMID: 21983557
   PubMedGoogle Scholar
• Li R, Chen DF, Zhou R, Jia SN, Yang JS, Clegg JS, Yang WJ. Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade. J Biol Chem 2012; 287:15923 - 34; http://dx.doi.org/10.1074/jbc.M111.312413; PMID: 22427657
   PubMed Web of Science ®Google Scholar
• Gangarossa G, Valjent E. Regulation of the ERK pathway in the dentate gyrus by in vivo dopamine D1 receptor stimulation requires glutamatergic transmission. Neuropharmacology 2012; 63:1107 - 17; http://dx.doi.org/10.1016/j.neuropharm.2012.06.062; PMID: 22796106
   PubMed Web of Science ®Google Scholar
• Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013; 3:1156 - 71; http://dx.doi.org/10.1158/2159-8290.CD-12-0595; PMID: 23887393
   PubMed Web of Science ®Google Scholar
• Cunningham JT, Ruggero D. New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization. Cancer Discov 2013; 3:1099 - 102; http://dx.doi.org/10.1158/2159-8290.CD-13-0581; PMID: 24124229
   PubMed Web of Science ®Google Scholar
• Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 2013; •••; http://dx.doi.org/10.1038/leu.2013.369; PMID: 24310736
   PubMed Web of Science ®Google Scholar
• Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle 2012; 11:2467 - 75; http://dx.doi.org/10.4161/cc.20859; PMID: 22713244
   PubMed Web of Science ®Google Scholar
• Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012; 3:1615 - 28; PMID: 23271044
   PubMed Web of Science ®Google Scholar
• Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 2012; 3:811 - 23; PMID: 22885370
   PubMed Web of Science ®Google Scholar
• Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, et al. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia 2014; 28:543 - 53; http://dx.doi.org/10.1038/leu.2013.349; PMID: 24253024
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar